OncoMatch/Clinical Trials/NCT06647940
Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients（Rocket Trial）
Is NCT06647940 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Orelabrutinib Oral Tablet and R-CHOP Protocol for diffuse large b cell lymphoma (dlbcl).
Treatment: Orelabrutinib Oral Tablet · R-CHOP Protocol — This is a prospective, single-arm, multicenter, phase II clinical trial to evaluate the efficacy and safety of orelabrutinib combined with the R-CHOP (rituximab, cyclophosphamide, vincristine, doxorubicin, and prednisone) regimen as first-line treatment in CD5-positive diffuse large B-cell lymphoma (DLBCL) patients.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD5 overexpression
CD5-positive DLBCL
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: btk inhibitor
Lab requirements
Blood counts
sufficient bone marrow function
Kidney function
sufficient kidney function
Liver function
sufficient liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06647940 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior btk inhibitor disqualifies patients from enrollment.
Does this trial require CD5?
Yes, CD5 overexpression is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify